Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies

Bibliography

• Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Substance Abuse and Mental Health Services Administration, Rockville, MD; 2013
   Google Scholar
• National Survey of Drug Use and Health (NSDUH). Substance Abuse and Mental Health Services Administration. SAMHSA, Washington, DC; 2014. Available from: www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/DetTabs/NSDUH-DetTabsTOC2012.htm [Last accessed 12 July 2014]
   Google Scholar
• Degenhardt L, Hall W. Extent of illicit drug use and dependence, and the contribution to the global burden of disease. Lancet 2012;379:55-70
   PubMed Web of Science ®Google Scholar
• Bertschy G. Methadone maintenance treatment: an update. Eur Arch Psych Clinical Neurosci 1995;245:114-24
   PubMed Web of Science ®Google Scholar
• Polomeni P, Schwan R. Management of opioid addiction with buprenorphine: french history and current management. Int J Gen Med 2014;7:143-8
   PubMedGoogle Scholar
• Auriacombe M, Fatseas M, Dubernet J, et al. French field experience with buprenorphine. Am J Addict 2004;13:S17-28
   PubMed Web of Science ®Google Scholar
• Kumar MS, Natale RD, Langkham B, et al. Opioid substitution treatment with sublingual buprenorphine in manipur and nagaland in northeast india: what was been established needs to be continued and expanded. Harm Reduct J 2009;6:4
   PubMedGoogle Scholar
• Lintzeris N, Ritter A, Panjari M, et al. Implementing buprenorphine treatment in community settings in australia: experiences from the Buprenorphine Implementation Trial. Am J Addict 2004;13:S29-41
   PubMed Web of Science ®Google Scholar
• Bridge TP, Fudala PJ, Herbert S, et al. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend 2003;70:S79-85
   PubMed Web of Science ®Google Scholar
• Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend 2000;58:143-52
   PubMed Web of Science ®Google Scholar
• Amass L, Kamien JB, Mikulich SK. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend 2001;61:173-81
   PubMed Web of Science ®Google Scholar
• Petry NM, Bickel WK, Badger GJ. Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens. Addiction 2001;96:823-34
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Bigelow GE, et al. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 1995;274:361-72
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994;55:569-80
   PubMed Web of Science ®Google Scholar
• Kosten TR, Kleber HD. Opioid detoxification using buprenorphine. NIDA Research Monograph 1988;90
   Google Scholar
• Greenwald MK, Johanson CE, Moody DE, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003;28:2000-9
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014;2:CD002207
   PubMed Web of Science ®Google Scholar
• Parran TV, Adelman CA, Merkin B, et al. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend 2010;106:56-60
   PubMed Web of Science ®Google Scholar
• Schwarz R, Zelenev A, Bruce RD, et al. Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. J Subst Abuse Treat 2012;43:451-7
   PubMed Web of Science ®Google Scholar
• Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011;4:CD001333
   PubMedGoogle Scholar
• Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend 2003;70:S59-77
   PubMed Web of Science ®Google Scholar
• Douglas Bruce R, Moody DE, et al. Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. Am J Drug Alcohol Abuse 2013;39:80-5
   PubMed Web of Science ®Google Scholar
• Gruber VA, Rainey PM, Moody DE, et al. Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir. Clin Infect Dis 2012;54:414-23
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Weiss L, Botsko M, et al. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr 1999;56:S33-8
   Google Scholar
• Korthuis PT, Tozzi MJ, Nandi V, et al. Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr 1999;56:S39-45
   Google Scholar
• Springer SA, Qiu J, Saber-Tehrani AS, et al. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS One 2012;7:e38335
   PubMed Web of Science ®Google Scholar
• Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr 1999;56:S22-32
   Google Scholar
• Neumann AM, Blondell RD, et al. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. J Addict Dis 2013;32:68-78
   PubMed Web of Science ®Google Scholar
• Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA 2008;300:2003-11
   PubMed Web of Science ®Google Scholar
• Smyth BP, Fagan J, Kernan K. Outcome of heroin-dependent adolescents presenting for opiate substitution treatment. J Subst Abuse Treat 2012;42:35-44
   PubMedGoogle Scholar
• Soyka M. Buprenorphine use in pregnant opioid users: a critical review. CNS Drugs 2013;27:653-62
   PubMedGoogle Scholar
• Bruce RD, Altice FL. Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases. Am J Drug Alcohol Abuse 2007;33:869-74
   PubMed Web of Science ®Google Scholar
• Saxon AJ, Ling W, Hillhouse M, et al. Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend 2013;128:71-6
   PubMed Web of Science ®Google Scholar
• Zuin M, Giorgini A, Selmi C, et al. Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. Dig Liver Dis 2009;41:e8-e10
   PubMedGoogle Scholar
• Yokell MA, Zaller ND, Green TC, et al. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Current Drug Abuse Rev 2011;4:28-41
   PubMedGoogle Scholar
• Soeffing JM, Martin LD, Fingerhood MI, et al. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat 2009;37:426-30
   PubMed Web of Science ®Google Scholar
• Moore BA, Fiellin DA, Barry DT, et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Int Med 2007;22:527-30
   PubMed Web of Science ®Google Scholar
• Dreifuss JA, Griffin ML, Frost K, et al. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: results from a multisite study. Drug Alcohol Depend 2013;131:112-18
   PubMed Web of Science ®Google Scholar
• Sullivan LE, Chawarski M, O’Connor PG, et al. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend 2005;79:113-16
   PubMed Web of Science ®Google Scholar
• Neumann AM, Blondell RD, Azadfard M, et al. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment. Addict Behav 2013;38:2724-8
   PubMed Web of Science ®Google Scholar
• Sullivan LE, Moore BA, O’Connor PG, et al. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. Am J Addict 2010;19:53-8
   PubMed Web of Science ®Google Scholar
• Cunningham CO, Giovanniello A, Kunins HV, et al. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users. Am J Addict 2013;22:352-7
   PubMed Web of Science ®Google Scholar
• Gerra G, Somaini L, Leonardi C, et al. Association between gene variants and response to buprenorphine maintenance treatment. Psychiatry Res 2014;215:202-7
   PubMed Web of Science ®Google Scholar
• Clarke TK, Crist RC, Ang A, et al. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in european-american females. Pharmacogenomics J 2014;14:303-8
   PubMedGoogle Scholar
• Crist RC, Clarke TK, Ang A, et al. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology 2013;38:2003-10
   PubMed Web of Science ®Google Scholar
• Arfken CL, Johanson CE, di Menza S, et al. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J Subst Abuse Treat 2010;39:96-104
   PubMed Web of Science ®Google Scholar
• Gordon AJ, Liberto J, Granda S, et al. Outcomes of DATA. 2000 certification trainings for the provision of buprenorphine treatment in the veterans health administration. Am J Addict 2008;17:459-62
   PubMed Web of Science ®Google Scholar
• Hutchinson E, Catlin M, Andrilla CH, et al. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med 2014;12:128-33
   PubMed Web of Science ®Google Scholar
• Walley AY, Alperen JK, Cheng DM, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Int Med 2008;23:1393-8
   PubMed Web of Science ®Google Scholar
• Quest TL, Merrill JO, Roll J, et al. Buprenorphine therapy for opioid addiction in rural washington: the experience of the early adopters. J Opioid Manag 2012;8:29-38
   PubMedGoogle Scholar
• Cunningham CO, Sohler NL, McCoy K, et al. Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med 2006;38:336-40
   PubMed Web of Science ®Google Scholar
• Thomas CP, Reif S, Haq S, et al. Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists. Psychiatr Serv 2008;59:909-16
   PubMed Web of Science ®Google Scholar
• Kennedy J, Dipzinski A, Roll J, et al. Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA. Drug Alcohol Depend 2011;114:201-6
   PubMed Web of Science ®Google Scholar
• Sohler NL, Weiss L, Egan JE, et al. Consumer attitudes about opioid addiction treatment: a focus group study in New York City. J Opioid Manag 2013;9:111-19
   PubMedGoogle Scholar
• Johanson CE, Arfken CL, di Menza S, et al. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend 2012;120:190-5
   PubMed Web of Science ®Google Scholar
• Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007;88:75-8
   PubMed Web of Science ®Google Scholar
• Uosukainen H, Kauhanen J, Voutilainen S, et al. Twelve-year trend in treatment seeking for buprenorphine abuse in Finland. Drug Alcohol Depend 2013;127:207-14
   PubMedGoogle Scholar
• Albright J, Ciaverelli R, Essex A, et al. Psychiatrist characteristics that influence use of buprenorphine medication-assisted treatment. J Addict Med 2010;4:197-203
   PubMed Web of Science ®Google Scholar
• Barry DT, Irwin KS, Jones ES, et al. Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Int Med 2009;24:218-25
   PubMed Web of Science ®Google Scholar
• Cunningham CO, Kunins HV, Roose RJ, et al. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Int Med 2007;22:1325-9
   PubMed Web of Science ®Google Scholar
• Gordon AJ, Kavanagh G, Krumm M, et al. Facilitators and barriers in implementing buprenorphine in the veterans health administration. Psychol Addict Behav 2011;25:215-24
   PubMed Web of Science ®Google Scholar
• Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat 2009;36:244-51
   PubMed Web of Science ®Google Scholar
• Quest TL, Merrill JO, Roll J, et al. Buprenorphine therapy for opioid addiction in rural Washington: the experience of the early adopters. J Opioid Manag 2012;8:29-38
   PubMedGoogle Scholar
• Smith K, Hopp M, Mundin G, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther 2012;50:360-7
   PubMed Web of Science ®Google Scholar
• Harris DS, Jones RT, Welm S, et al. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 2000;61:85-94
   PubMed Web of Science ®Google Scholar
• Lavonas EJ, Banner W, Bradt P, et al. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children. J Pediatr 2013;163:1235-9
   Google Scholar
• Lavonas EJ, Severtson SG, Martinez EM, et al. Abuse and diversion of buprenorphine sublingual tablets and film. J Subst Abuse Treat 2014;47:27-34
   PubMed Web of Science ®Google Scholar
• Sigmon SC, Moody DE, Nuwayser ES, et al. An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction 2006;101:420-32
   PubMed Web of Science ®Google Scholar
• Sigmon SC, Wong CJ, Chausmer AL, et al. Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction 2004;99:1439-49
   PubMed Web of Science ®Google Scholar
• Sobel BF, Sigmon SC, Walsh SL, et al. Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug Alcohol Depend 2004;73:11-22
   PubMed Web of Science ®Google Scholar
• Ling W, Mooney L, Zhao M, et al. Selective review and commentary on emerging pharmacotherapies for opioid addiction. Subst Abuse Rehabil 2011;2:181-8
   PubMedGoogle Scholar
• White J, Bell J, Saunders JB, et al. Open-label dose-finding trial of buprenorphine implants (probuphine) for treatment of heroin dependence. Drug Alcohol depend 2009;103:37-43
   PubMed Web of Science ®Google Scholar
• Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. Jama 2010;304:1576-83
   PubMed Web of Science ®Google Scholar
• Rosenthal RN, Ling W, Casadonte P, et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction 2013;108:2141-9
   PubMed Web of Science ®Google Scholar
• Kunins HV, Sohler NL, Giovanniello A, et al. A buprenorphine education and training program for primary care residents: implementation and evaluation. Subst Abus 2013;34:242-7
   PubMed Web of Science ®Google Scholar
• Lofwall MR, Wunsch MJ, Nuzzo PA, et al. Efficacy of continuing medical education to reduce the risk of buprenorphine diversion. J Subst Abuse Treat 2011;41:321-9
   PubMed Web of Science ®Google Scholar
• Reifler LM, Droz D, Bailey JE, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med 2012;13:434-42
   PubMed Web of Science ®Google Scholar
• Curtis LH, Stoddard J, Radeva JI, et al. Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Serv Res 2006;41:837-55
   PubMed Web of Science ®Google Scholar
• Paulozzi LJ, Kilbourne EM, Shah NG, et al. A history of being prescribed controlled substances and risk of drug overdose death. Pain Med 2012;13:87-95
   PubMed Web of Science ®Google Scholar
• Surratt HL, O’Grady C, Kurtz SP, et al. Reductions in prescription opioid diversion following recent legislative interventions in Florida. Pharmacoepidemiol Drug Saf 2014;23:314-20
   PubMed Web of Science ®Google Scholar
• Ducharme LJ, Abraham AJ. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy 2008;3:17
   PubMed Web of Science ®Google Scholar
• Gunderson EW, Wang XQ, Fiellin DA, et al. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. Addict Behav 2010;35:537-40
   PubMed Web of Science ®Google Scholar
• Sohler NL, Li X, Kunins HV, et al. Home- versus office-based buprenorphine inductions for opioid-dependent patients. J Subst Abuse Treat 2010;38:153-9
   PubMed Web of Science ®Google Scholar
• Lee JD, Grossman E, DiRocco D, et al. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med 2009;24:226-32
   PubMed Web of Science ®Google Scholar
• Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med 2011;171:425-31
   PubMed Web of Science ®Google Scholar
• Hersh D, Little SL, Gleghorn A. Integrating buprenorphine treatment into a public healthcare system: the San Francisco Department of Public Health’s office-based Buprenorphine Pilot Program. J Psychoactive Drugs 2011;43:136-45
   PubMed Web of Science ®Google Scholar
• Kakko J, Gronbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007;164:797-803
   PubMed Web of Science ®Google Scholar